Drug Master Files for: CLOFAZIMINE
✉ Email this page to a colleague
CLOFAZIMINE Drug Master Files
DMF No. | Status | Type | Submission Date | Holder | Subject |
---|---|---|---|---|---|
16668 | A | II | 6/26/2003 | SANDOZ PRIVATE LTD | CLOFAZIMINE |
25326 | I | II | 9/28/2011 | SANGROSE LABORATORIES PVT LTD | CLOFAZIMINE |
31256 | A | II | 12/21/2016 | ZHEJIANG HUAHAI PHARMACEUTICAL CO LTD | CLOFAZIMINE USP |
33157 | A | II | 9/6/2018 | OLON SPA | CLOFAZIMINE |
3527 | I | II | 5/4/1979 | CIBA GEIGY CORP PHARMACEUTICAL DIVISION | LAMPRENE (CLOFAZIMINE) AS PRODUCED IN CAPSULE FORM |
>DMF No. | >Status | >Type | >Submission Date | >Holder | >Subject |
Drug Master File Glossary
STATUS OF DMFS
- A = Active. This means that the DMF was found acceptable for filing, administratively, and is up-to-date.
- I = Inactive
- N = Not an assigned number
- P = DMF Pending Filing Review
TYPES OF DMFs
- Type I Manufacturing Site, Facilities, Operating Procedures, and Personnel (no longer applicable)
- Type II Drug Substance, Drug Substance Intermediate, and Material Used in Their Preparation, or Drug Product
- Type III Packaging Material
- Type IV Excipient, Colorant, Flavor, Essence, or Material Used in Their Preparation
- Type V FDA Accepted Reference Information